Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

91.48 +0.53 (+0.59%)
Streaming Delayed Price Updated: 2:32 PM EST, Nov 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday. 
Via Investor's Business Daily
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
The company is adding onto its success outperforming Merck's top drug in lung cancer patients. 
Via Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab. 
Via MarketBeat
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
From Merck & Co., Inc.
Via Business Wire
What's Wrong With Merck's Stock?
Is the healthcare stock an underrated buy right now? 
Via The Motley Fool
Is Summit Therapeutics a Buy Now?
The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug. 
Via The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
The company's new lung cancer treatment could unseat Merck's Keytruda in the $50 billion-plus lung cancer treatment market. 
Via The Motley Fool
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda. The biotech stock rallied 30%. 
Via Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Summit Therapeutics shared Phase 3 HARMONi-2 trial data of ivonescimab, showing significant improvement in progression-free survival compared to Merck's Keytruda in non-small cell lung cancer patients,... 
Via Benzinga
(MRK) - Analyzing Merck & Co's Short Interest
 
Via Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
 
Via Benzinga
Uncovering Dividend Opportunities with NYSE:MRK.
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. 
Via Chartmill
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in September
These stocks pay great dividends and could be long-term winners. 
Via The Motley Fool
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
From Daiichi Sankyo
Via Business Wire
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant? 
Via MarketBeat
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out? 
Via MarketBeat
What's Going On With Merck Shares Thursday?
Merck stock is trading higher on Thursday after the company announced it completed negotiations with the pan-Canadian Pharmaceutical Alliance. 
Via Benzinga
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Could this beaten-down stock turn things around in the near future? 
Via The Motley Fool
The Smartest Dividend Stocks to Buy With $5,000 Right Now
These stocks have a long history of increasing dividends. 
Via The Motley Fool
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
From Merck & Co., Inc.
Via Business Wire
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
From Merck & Co., Inc.
Via Business Wire
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck flirts with bearish trends; Gilead is on a golden streak. Who wins? Investors should keep an eye on these diverging technical signals. 
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
From Merck & Co., Inc.
Via Business Wire
2 Dividend Stocks You Can Safely Hold Through a Recession
These stocks can help you sleep peacefully at night, even in bad times. 
Via The Motley Fool
Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales
BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and... 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.